Motilal Oswal
Upgrades to âbuyâ with a target price of Rs 870 apiece.
Sudhir Sitapatiâs appointment as MD and CEO is a potentially transformative event in the fortunes of the company.
His appointment as MD and CEO for five years, as well as his relative young age (mid-40s), gives him adequate time to formulate and implement strategic changes.
The underpenetrated household insecticides and hair color categories could greatly benefit from Sitapatiâs past experience, where GCPL has struggled to boost penetration.
Valuations, which are deservedly at a discount of 10% to large-cap staples peers given the weak growth and lower return on capital employed, will change with the potentially transformative changes that Sitapati can usher in.
Godrej Consumer Products Ltd posts consolidated PAT of Rs 365 84 crore in Q4FY21 equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
FMCG major Godrej Consumer Products Ltd (GCPL) on Tuesday reported a 59.13 per cent increase in its consolidated net profit to Rs 365.84 crore for the fourth quarter ended March 2021. The company, whose board on Tuesday appointed HUL former executive director Sudhir Sitapati as the managing director and CEO, had posted a net profit of Rs 229.90 crore in the January-March quarter a year ago, GCPL said in a BSE filing. Its net sales during the January-March 2021 were up by 26.87 per cent to Rs 2,705.69 crore, against Rs 2,132.69 crore in the year-ago period. GCPL Chairperson and Managing Director Nisaba Godrej said, We delivered a third consecutive quarter of double-digit sales growth. Consolidated sales grew 27 per cent and Ebitda (earnings before interest, tax, depreciation and amortisation) grew by 21 per cent.
Representational Image
During the second wave of COVID-19, stocks of pharmaceutical, oxygen and other companies involved in tackling COVID-19 have been in focus. But today, there may be some pharmaceutical stocks that may draw more attention of investors.
Given is the list of stocks:
Cipla and Jubilant Life Sciences: Both these stocks may buzz when the market opens today. This is because the Karnataka government on Tuesday served notices to pharmaceutical majors Cipla and Jubilant warning them of legal proceedings for not supplying adequate quantities of Remdesivir injection bottles as directed by the Government of India. In a notice to the pharmaceutical companies, the Principal Secretary in the Revenue department N Manjunatha Prasad said they were ordered to deliver 62,000 vials of Remdesivir injection, but they supplied very less consignment. Cipla and Jubilant were ordered to supply 30,000 and 32,000 vials respectively by May 9. However, they supplied only 10,840 and 17,601 v
Share this article
NEW YORK, May 10, 2021 /PRNewswire/
The mosquito repellent market is expected to grow by USD 3.60 billion during 2021-2025, according to Technavio. The report offers a detailed analysis of the impact of the COVID-19 pandemic on the mosquito repellent market in optimistic, probable, and pessimistic forecast scenarios.
Technavio has announced its latest market research report titled Mosquito Repellent Market by Product and Geography - Forecast and Analysis 2021-2025
Enterprises will go through the Response, Recovery, and Renew phases.
The mosquito repellent market will witness a positive impact during the forecast period owing to the widespread growth of the COVID-19 pandemic. As per Technavio s pandemic-focused market research, market growth is likely to increase in 2021 as compared to 2020.